fbpx
01 / 05
HIV Vaccine Triggers Rare and Elusive Antibodies in Humans

Live Science | Vaccination

HIV Vaccine Triggers Rare and Elusive Antibodies in Humans

“Vaccines typically work by eliciting a similar immune reaction to what’s seen during a real infection. But in the case of HIV, vaccine developers have to dramatically expedite the process, calling forth antibodies in weeks that would usually take years to show up. 

Now, in a study published Friday (May 17) in the journal Cell, scientists have demonstrated that this feat is possible in humans…

The trial included 20 HIV-negative volunteers. Fifteen received two vaccine doses, spaced two months apart, while the remaining five got a third dose four months after their second. Tests showed that two doses of vaccine triggered a robust response from immune cells and kicked off the production of broadly neutralizing antibodies. The team further confirmed the presence of these antibodies in the three-dose group by closely analyzing their immune cells.”

From Live Science.

Gavi | Vaccination

Mali Rolls Out Cancer-Blocking Jab

“In a historic move, the government of Mali has introduced the human papillomavirus (HPV) vaccine into its routine immunisation programme. During a ceremony held in Bamako earlier this month, and attended by numerous dignitaries and international partners, Gavi and the Ministry of Health and Social Development emphasised the importance of this initiative, terming it a significant step forward in preventing cervical cancer among Malian women.”

From Gavi.

World Health Organization | Vaccination

Cross-Border Polio Vaccination Reaches 6.5 Million Children

“Between October 3 and 6, 2024, more than 6.5 million children were vaccinated in a successful synchronized polio campaign between Kenya and Uganda. This cross-border achievement began with a coordinated launch in Bungoma District, Kenya, and Mbale District, Uganda. 

Both countries have set an exemplary standard in their recent synchronized polio vaccination campaign conducted this week, which focused on high-risk cross-border regions. By conducting these campaigns on the same dates, sharing real-time information, both countries ensured that children under five in these vulnerable areas were reached effectively, reducing the chance of cross-border virus transmission.”

From World Health Organization.

The Guardian | Vaccination

Doctors Trial mRNA Vaccine Against Vomiting Bug Norovirus

“Doctors have begun trialling the world’s first mRNA vaccine against the vomiting bug norovirus in the hope the jab could bring huge health and economic benefits.

Norovirus causes sickness and diarrhoea and can spread very rapidly between people who are in close contact, with outbreaks often occurring in hospitals, care homes, schools and nurseries.

While most people recover within two to three days, the virus can be serious, particularly for the very young, elderly or people with a weakened immune system…

Called Nova 301, the phase 3 clinical trial is to run for two years, and will enrol 25,000 adults – with a focus on those over the age of 60 – from countries including Japan, Canada and Australia.”

From The Guardian.